Das Produkt wurde korrekt in den Warenkorb gelegt.

discount label
13C-PT630
3D-Ansicht

Biosynth logo

13C-PT630

Ref. 3D-PP47011

Unbestimmte GrößeNachfragen
Voraussichtliche Lieferung in Vereinigte Staaten, am Dienstag 29. Oktober 2024

Produktinformation

Name:
13C-PT630
Synonyme:
  • 13Cys-PT630
Beschreibung:

Peptide 13C-PT630 is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using 13C-PT630 include the following: Ming-Hui Fan1, Qiang Zhu2, Hui-Hua Li1, Hyun-Jeong Ra3, Sonali Majumdar4, Dexter L. Gulick1, Jacob A. Jerome1, Daniel H. Madsen5, Melpo Christofidou WW Bachovchin, C Feghali-Bostwick, E Pure - 2015 - researchgate.nethttps://www.researchgate.net/profile/Rajrupa-Majumdar/publication/286643393_Fibroblast_Activation_Protein_FAP_Accelerates_Collagen_Degradation_and_Clearance_from_Lung_in_Mice/links/57a7dbeb08ae3f4529393057/Fibroblast-Activation-Protein-FAP-Accelerates-Collagen-Degradation-and-Clearance-from-Lung-in-Mice.pdf Stromal Gene Signatures as Source of Targets for Drug-Repositioning and Prognostic Biomarkers in Prostate Cancer V Doldi - 2020 - search.proquest.comhttps://search.proquest.com/openview/776abcf67baabd4b186f8aa7fe471442/1?pq-origsite=gscholar&cbl=2026366&diss=y Dipeptidyl Peptidase Inhibition Decreases Osteosarcoma Tumor Formation by Targeting Stromal Elements and Immune Stimulation SY Kim , M Guimond, HJ Meany, S Strahan - Journal of , 2006 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/fulltext/2006/11000/dipeptidyl_peptidase_inhibition_decreases.179.aspx Preclinical assessment of fibroblast activation protein as a target for antitumor therapy SW Hayward - Future Oncology, 2010 - Future Medicinehttps://www.futuremedicine.com/doi/abs/10.2217/fon.10.8 Fibroblast activation protein: A potential therapeutic target in cancer R Liu, H Li, L Liu, J Yu, X Ren - Cancer biology & therapy, 2012 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.4161/cbt.13.3.18696 Targeting fibroblast activation protein in cancer-Prospects and caveats P Busek , R Mateu, M Zubal, L Kotackova - Biosci (Landmark Edhttps://www.researchgate.net/profile/Aleksi-Sedo/publication/325500629_Targeting_Fibroblast_activation_protein_in_cancer_-_Prospects_and_caveats/links/64d3aef5c80b930269fb6409/Targeting-Fibroblast-activation-protein-in-cancer-Prospects-and-caveats.pdf Review of cancer-associated fibroblasts and therapies that interfere with their activity N Takebe, P Ivy, W Timmer, N Khan - Tumor , 2013 - researchgate.nethttps://www.researchgate.net/profile/Pamela-Harris-7/publication/258879070_Cancer-associated_Fibroblasts_and_Therapies_That_Interfere_with_Their_Activity/links/02e7e5294e59555443000000/Cancer-associated-Fibroblasts-and-Therapies-That-Interfere-with-Their-Activity.pdf Immune Cytolysis Induces HMGB1 Release Through a Partially Caspase Dependent Apoptotic Pathway N Ito, RA Demarco, RB Mailliard , J Han - Journal of , 2006 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/fulltext/2006/11000/Immune_Cytolysis_Induces_HMGB1_Release_Through_a.178.aspx Fibroblast activation protein in remodeling tissues M Jacob, L Chang, E Pure - Current molecular medicine, 2012 - ingentaconnect.comhttps://www.ingentaconnect.com/content/ben/cmm/2012/00000012/00000010/art00002 Activation of fibroblasts in cancer stroma K Rasanen, A Vaheri - Experimental cell research, 2010 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S001448271000203X Immunoediting of Cancers may Lead to Epithelial to Mesenchymal Transition JM Reiman, MD Behrens, ML Disis - Journal of , 2006 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/fulltext/2006/11000/Immunoediting_of_Cancers_may_Lead_to_Epithelial_to.180.aspx Pituitary Tumor Transforming Gene 1 is Expressed in Kupffer Cells, Activated T Lymphocytes and a Proportion of Primary Liver Cancer Cells F Grizzi , S Musardo, B Franceschini - Journal of , 2006 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/fulltext/2006/11000/Pituitary_Tumor_Transforming_Gene_1_is_Expressed.177.aspx The road to integrative cancer therapies: emergence of a tumor-associated fibroblast protease as a potential therapeutic target in cancer E Pure - Expert Opinion on Therapeutic Targets, 2009 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1517/14728220903103841 Targeting Fibroblasts in Fibrosis and Cancer AMRH Mostafa, R Bansal, J Prakash - 2020 - books.rsc.orghttps://books.rsc.org/books/edited-volume/824/chapter/565242 Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice AM Santos, J Jung, N Aziz , JL Kissil - The Journal of clinical , 2009 - Am Soc Clin Investighttps://www.jci.org/articles/view/38988 Investigation of the biological function of fibroblast activation protein and its potential as a therapeutic target in cancer and diabetes AL Coppage - 2015 - search.proquest.comhttps://search.proquest.com/openview/5b0bf4450b38d799a268bcadef876450/1?pq-origsite=gscholar&cbl=18750

Hinweis:
Unsere Produkte sind nur für Laborzwecke. Für jede andere Verwendung, bitte melden sie sich bei uns.
Marke:
Biosynth
Langzeitlagerung:
Hinweise:

Chemische Eigenschaften

MDL:
Schmelzpunkt:
Siedepunkt:
Flammpunkt:
Dichte:
Konzentration:
EINECS:
Merck:
HS-Code:

Gefahrenhinweise

UN-Nummer:
EQ:
Klasse:
H-Sätze:
P-Sätze:
Flugverbot:
Gefahrenhinweis:
Verpackungsgruppe:
LQ:

Technische Anfrage zu: 3D-PP47011 13C-PT630

Bitte verwenden Sie stattdessen den Warenkorb, um ein Angebot oder eine Bestellung anzufordern

Wenn Sie ein Angebot anfordern oder eine Bestellung aufgeben möchten, legen Sie stattdessen die gewünschten Produkte in Ihren Warenkorb und fordern Sie dann ein Angebot oder eine Bestellung an aus dem Warenkorb. Es ist schneller, billiger und Sie können von den verfügbaren Rabatten und anderen Vorteilen profitieren.

* Obligatorische felder
Willkommen bei CymitQuimica!Wir verwenden Cookies, um Ihren Besuch zu verbessern. Wir schließen Werbung nicht ein.

Bitte beachten Sie unsere Cookie-Richtlinie  für weitere Details oder passen Sie Ihre Einstellungen unter “Konfigurieren” an.